Last reviewed 2026-04-23 · How we verify

ARGX-117

ARGX-117 is a monoclonal antibody targeting CD70.

ARGX-117 is a monoclonal antibody targeting CD70. Used for Treatment of generalized myasthenia gravis.

At a glance

Mechanism of action

ARGX-117 works by binding to CD70, a protein involved in the activation of immune cells. This binding leads to the depletion of CD70-expressing immune cells, which are thought to contribute to autoimmune diseases. By reducing the activity of these cells, ARGX-117 aims to alleviate symptoms and slow disease progression.

Approved indications

• Treatment of generalized myasthenia gravis

Common side effects

• Injection site reactions

Key clinical trials

• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (PHASE2)
• A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (PHASE2)
• A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (PHASE2)
• A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy (PHASE2)
• SAD and MAD Study With IV and SC Doses of ARGX-117 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ARGX-117 CI brief — competitive landscape report
• ARGX-117 updates RSS · CI watch RSS
• argenx portfolio CI